|What am I going to do now, Nelson?
Aug 6, 2010
Hi Nelson, I hope all is well. Last year you told me about the trial with ibalizumab at ACRIA and I received the meds for about 1 year. In the beginning of thet trial the virus became undectadable but then it started to go up again and they took me out of the study. I was in the trial for about 1 year. My doctor changed my regimen to recycle meds…I’m resistant to all of them. I am now on Aptivus, Viread, Norvir and Trizivir. Do you know of any other trials in NYC? Thanks for your help.
|Response from Mr. Vergel
I am so sorry that your virus developed resistance to ibalizumab (Taimed’s intravenous CD4 monoclonal antibody that may be given once every two weeks).
I am working with ACRIA and two San Francisco doctors in setting up a small expanded access pilot to combine two investigational agents by early summer 2011, but we are still waiting for data. But it is not a done deal. However, one of the drugs may be ibalizumab.
GSK-ViiV are testing a second generation integrase inhibitor (GSK572) in phase II now and we are really hoping it can help people with raltegravir resistance. Some preliminary data show that it may help those with certain integrase mutations. GSK is also testing two non nucleosides in early phase 2. So, it will take at least 8 months to know where we are going with these agents.
AVEXA, an Australian company that has an interesting nucleoside, may be back in the picture after their board reconsidered not dropping their drug due to activist pressure. I am following that drug closely also.
BMS seems to have an entry inhibitor but they are a company that does not like to share information with treatment activists, so it has been a challenge to get them to tell us anything. It is unfortunate that in 2010 we still have this lack of communication going (but they are rare among companies).
Progenics also had a once a week subcutaneous entry inhibitor that looks very exciting. They are also a company that has refused to meet with treatment activists. They are small and may not understand the power that activists have in the present to help advocate for new drugs.
Koronis (http://www.koronispharma.com/KP1461forHIV.html) also has an interesting nucleoside that works very differently than the ones we have right now, but they have not tested it in people like you with a failing regimen.
Some of these companies may or may not agree to provide drug in a compassionate manner for one patient (but remember that you need at least two new active drugs to avoid functional monotherapy). But if your doctor wants to ask them, the FDA has set up a way to do so provided that the companies are willing to help. The FDA procedure is http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm163982.htm
Chemical engineer, 34+ year HIV and cancer survivor, health author and educator . Founder of DiscountedLabs.com , ExcelMale.com , and PowerUSA.org
From: “News at The Body” <firstname.lastname@example.org> Date: 26 Jul 2011 18:20:45 -0400 To: <email@example.com> ReplyTo: “News at The... read more
A kidney drug was able to decrease gut related immune activation in monkeys http://www.poz.com/articles/leaking_gut_761_25741.shtml read more
From: “News at The Body” <firstname.lastname@example.org> Date: 06 Jun 2012 12:06:09 -0400 To: <email@example.com> ReplyTo: “News at The... read more
Two companies have an effective 100% cure for Hepatitis C without interferon or ribavirin. But this cure is literally being withheld from millions... read more
Staying on top of your treatment every day is not an easy task. Annoying side effects, being disorganized and... read more
Two-Year Longitudinal Analysis of a Cluster Randomized Trial of Physical Activity Promotion by General Practitioners Article Metrics Related Content Comments: 0 To add a note,... read more
Timothy Ray Brown, aka “The Berlin Patient,” is the first person to be declared cured of HIV. A Seattle... read more
Nelson Vergel explains each one of the steps that need to be taken after a HIV diagnosis. read more